Immunogen (IMGN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
ImmunoGen has successfully completed its merger and, in the process, settled all outstanding obligations under its previous Loan Agreement, releasing all collateral tied to it. Shareholders of common stock, excluding certain shares, received a cash payout of $31.26 per share, and all equity awards were fully vested or cancelled and settled in cash. Following the merger, trading of the company’s common shares on the Nasdaq ceased and steps were taken to delist the company, with plans to terminate all SEC reporting obligations. Additionally, the company’s board of directors was reconstituted, and its articles of organization and by-laws were fully amended and restated.
For further insights into IMGN stock, check out TipRanks’ Stock Analysis page.
